Jiangsu Hengrui Medicine
600276.SS
#463
Rank
C$60.97 B
Marketcap
$9.56
Share price
-1.68%
Change (1 day)
14.35%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): $0.12

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is $0.13. In 2022 the company made an earnings per share (EPS) of $0.13 a decrease over its 2021 EPS that were of $0.15.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.12-2.27%
2022$0.13-17.1%
2021$0.15-24.44%
2020$0.2020.3%
2019$0.1725.58%
2018$0.1327.55%
2017$0.1021.64%
2016$0.0855313.57%
2015$0.0753139.86%
2014$0.0538521.33%
2013$0.0443817.7%
2012$0.0377125.56%
2011$0.0300326.22%
2010$0.0237910.3%
2009$0.0215757.92%
2008$0.0136611.06%
2007$0.0123085.81%
2006$0.00661987.94%
2005$0.00352233.97%
2004$0.00262929.78%
2003$0.00202519.78%
2002$0.001691